Loading
Assure Holdings Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Price John C, was filed 22 Nov 2022.
Assure Holdings Corp.: what insiders have been doing
Every trade that managers of Assure Holdings Corp. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Assure Holdings Corp. The previous disclosure was published on 13 April 2023.
Since 2017, the database holds 8 purchases and 29 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Vivos Inc and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
86
Thresholds
n/a
Buy Volume
€337,715
8 ops. · all time
Sell Volume
€544,659
29 ops. · all time
Since the insiders bought
- -96.7%Entry US$154.80 · Close at T+365 US$5.15
- -96.7%Entry US$154.80 · Close at T+365 US$5.15
- -98.2%Entry US$242.82 · Close at T+365 US$4.42
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$255k
Gross profit-US$2.2M-860% margin
EBITDA-US$19.5M-7633% margin
Net income-US$26.1M-10226.7% margin
Valuation
Beta20266.27
Balance sheet & cash
Market capUS$1.6k
Total debtUS$14.8M
Free Cash Flow-US$5M
Profitability & ownership
ROA-89.3%
% insiders0.0%
% institutions0.0%
Last declaration on 13 April 2023
Declarations86 total
2,500 shares@ US$3.03163.3% of flowCommon StockSEC:0001886261-23-000013:0
500 shares@ US$3.3144.0% of flowCommon StockSEC:0001140361-23-017608:0
1,400 shares@ US$3.65572.2% of flowCommon StockSEC:0001886261-23-000012:0
480 shares@ US$4.4156.0% of flowCommon StockSEC:0001140361-23-017091:0
3,500 shares@ US$4.076.2% of flowCommon StockSEC:0001886261-23-000011:0
25,000 shares@ US$0.293.2% of flowcommon StockSEC:0001886261-23-000009:0
25,000 shares@ US$0.28623.1% of flowCommon StockSEC:0001886261-23-000008:0
14,000 shares@ US$0.3292.0% of flowCommon StockSEC:0001886261-23-000007:0
7,000 shares@ US$0.341.0% of flowCommon StockSEC:0001886261-23-000006:0
14,500 shares@ US$0.34552.2% of flowCommon StockSEC:0001886261-23-000005:0
18,000 shares@ US$0.33582.7% of flowCommon StockSEC:0001886261-23-000004:0
99,000 shares@ US$0.285112.7% of flowCommon StockSEC:0001886261-23-000003:0
10,000 shares@ US$0.281.2% of flowCommon StockSEC:0001886261-23-000002:0
94,000 shares@ US$0.292612.3% of flowCommon stockSEC:0001886261-23-000001:0
50,000 shares@ US$0.25055.6% of flowcommon stockSEC:0001886261-22-000005:0
70,615 shares@ US$0.6031.5% of flowCommon stockSEC:0001415889-22-011707:0
Canonical exit: 16 Feb 2023 (T+90)
67,713 shares@ US$0.6034.3% of flowCommon stockSEC:0001415889-22-011705:0
Canonical exit: 16 Feb 2023 (T+90)
62,170 shares@ €0.657992.2% of flowCommon stockSEC:0001415889-22-010857:0
3,000 shares@ US$6.19100.0% of flowCommon stockSEC:0001415889-22-010851:0
Canonical exit: 27 Feb 2022 (T+90)
3,000 shares@ US$6.19100.0% of flowCommon stockSEC:0001415889-22-010855:0
Canonical exit: 27 Feb 2022 (T+90)
3,000 shares@ US$6.19100.0% of flowCommon stockSEC:0001415889-22-010853:0
Canonical exit: 27 Feb 2022 (T+90)
155,132 shares@ US$2.752699.4% of flowCommon StockSEC:0001535264-22-000032:0
1,100 shares@ US$2.63090.6% of flowCommon StockSEC:0001535264-22-000031:0
16,200 shares@ CA$0.0004100.0% of flowCommon SharesTSXSEDI:3840340
8,100 shares@ CA$0.0008100.0% of flowCommon SharesTSXSEDI:3840329
25 of 86 declarations
About Assure Holdings Corp.
Assure Holdings Corp. (Nasdaq: IONM) is a U.S.-listed healthcare services company traded on the NASDAQ market in the United States. For international investors, the company is best understood as a specialized provider of intraoperative neuromonitoring, or IONM, a clinical service used during surgery to help monitor neural function in real time and reduce the risk of nerve injury. The business has historically operated as an outsourced service partner to surgeons, hospitals, and ambulatory surgery centers, with its administrative headquarters in Denver, Colorado. SEC filings show that the company’s operating footprint has evolved materially over time, and that its clinical activity was narrowed significantly in 2024.
Assure’s core offering is built around two service layers. The technical component is delivered in the operating room by trained neurophysiology personnel who monitor signals throughout procedures. The professional component is provided remotely by supervising practitioners, adding redundancy, clinical oversight, and risk mitigation. In practice, this model supports surgeries where the nervous system is at risk, including neurosurgery, spine surgery, orthopedic procedures, certain cardiovascular interventions, and ENT cases. This niche is highly dependent on clinical quality, staffing depth, surgeon relationships, reimbursement dynamics, and operational reliability.
Read moreShow less
The company’s modern operating structure dates back to 2016, when its Colorado subsidiary was formed, although the broader corporate history includes an older Canadian capital pool company origin that later became a Nevada corporation through domestication. Assure has been positioned as a specialized, technology-enabled healthcare services platform rather than a pure medical device company. Its competitive positioning has been based on procedural expertise and service quality, but recent filings indicate a more defensive posture as the company has worked through portfolio reshaping and strategic review.
A major recent development came in 2024, when Assure sold most of its clinical operations, equipment, and contracts. After that transaction, the company stated that it continued to provide IONM services only in limited markets, primarily Arizona and Montana. Assure also entered into a merger agreement with Danam Health in February 2024, but terminated that agreement in June 2024. Those events suggest that the business has been in transition, with management exploring strategic alternatives while trying to preserve value.
From an equity-analysis perspective, Assure should be viewed as a micro-cap healthcare situation with elevated execution and liquidity risk, rather than a stable operating franchise. The company remains relevant to investors following SEC Form 4 insider transactions, but the more important investment narrative today is restructuring, asset rationalization, and strategic optionality. In short, Assure is a small U.S. NASDAQ-listed healthcare services company whose recent history is defined less by expansion than by contraction and repositioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1798270/000179827024000012/ionm-20231231x10k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
